Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06542874 · ClinicalTrials.gov registry record · Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 448
- Enrollment target
NCT06542874: Completed Phase 2 study, sponsored by Novo Nordisk A/S.
NCT06542874 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 448 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (237% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06542874, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 448 participants
- Enrollment target
Study Summary
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Primary Outcome
percent point
Interventions
- DRUG NNC0487-0111 subcutanous
- DRUG Placebo (NNC0487-0111 subcutanous)
- DRUG NNC0487-0111 oral
- DRUG Placebo (NNC0487-0111 oral)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 448 participants |
| Start Date | 2024-08-07 |
| Est. Completion | 2025-10-24 |
| Phase | Phase 2 |
What the finished NCT06542874 record still lists
NCT06542874 is an interventional study that assigns participants to a tested intervention. The registered 448 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (237% higher).
The record links to 0 conditions, and to 4 interventions - of which NNC0487-0111 subcutanous is the first listed.
NCT06542874 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06542874 about?
NCT06542874 is a clinical study titled "A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes". The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get...
What is the current status of trial NCT06542874?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 448 participants. The study started on 2024-08-07. Estimated completion is 2025-10-24.
What interventions are being tested in trial NCT06542874?
The interventions under investigation include: NNC0487-0111 subcutanous (DRUG), Placebo (NNC0487-0111 subcutanous) (DRUG), NNC0487-0111 oral (DRUG), Placebo (NNC0487-0111 oral) (DRUG).
Who is sponsoring clinical trial NCT06542874?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06542874's enrollment target sits among peer trials
448 89th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06702449 · 448 participants · Phase 1
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
- NCT07125053 · 448 participants · NA
COPD Resources, Education, and Activity Designed for You Study
- NCT04065399 · 447 participants · Phase 1
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI